Lung Carcinoma Clinical Trial
Official title:
A Single-Arm Phase II Study of Personalized Dose Guidance for Stereotactic Body Radiotherapy (SBRT) in Patients With Lung Tumors
This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation therapy (SBRT) planning in patients with primary lung cancer or tumors that has spread from another primary site to the lung (metastatic). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Even with the high precision of SBRT, disease persistence or reappearance (local recurrence) can still occur, which could be attributed to the radiation dose. AI has been used in other areas of healthcare to automate and improve various aspects of medical science. Because the relationship of dose and local recurrence indicates that dose prescriptions matter, decision support systems to help guide dose based on personalized prediction AI algorithms could better assist providers in prescribing the radiation dose of lung stereotactic body radiation therapy treatment.
PRIMARY OBJECTIVE: I. To obtain preliminary evidence of efficacy (reduction in local failure free survival) in patients receiving SBRT to the lung with personalized artificial intelligence dose guidance (Deep Profiler + iGray). SECONDARY OBJECTIVES: I. To evaluate progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 in patients receiving individualized radiation doses to the lung as recommended by Deep Profiler + iGray. II. To evaluate respiratory function per the Radiation Therapy Oncology Group (RTOG) Pulmonary Function Scale. III. To assess toxicity per Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0 in patients receiving individualized radiation doses to the lung as recommended by Deep Profiler + iGray. IV. To evaluate the feasibility, defined as 85% receiving within 10% of the projected dose, of implementing the individualized radiation doses recommended by machine learning software (Deep Profiler + iGray) in a clinical practice. OUTLINE: Patients undergo radiation planning with AI-directed analysis for dose recommendations with Deep Profiler + iGray software on study. Patients then undergo SBRT on study. Patients also undergo positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), and/or x-ray imaging during screening and follow-up. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04931017 -
Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Not yet recruiting |
NCT06038526 -
Evaluation of Canakinumab in High-Risk Former-Smokers
|
Phase 2 | |
| Terminated |
NCT02856581 -
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
|
Phase 3 | |
| Completed |
NCT04922697 -
Educational Intervention for the Promotion of Knowledge and Preventive Health Behaviors Related to Personal Air Pollution Exposure, The Air Study
|
N/A | |
| Recruiting |
NCT04644952 -
The Rise in Robotic Atypical Segmentectomies
|
||
| Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
| Recruiting |
NCT05407168 -
Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool
|
N/A | |
| Completed |
NCT04267874 -
Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study
|
Early Phase 1 | |
| Recruiting |
NCT02408861 -
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Recruiting |
NCT03709953 -
Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03267524 -
Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers
|
N/A | |
| Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
| Completed |
NCT02237183 -
Iloprost in Preventing Lung Cancer in Former Smokers
|
Phase 1 | |
| Recruiting |
NCT04783168 -
Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study
|
N/A | |
| Completed |
NCT04635761 -
Awareness, Information, and Resources for Lung Cancer Screening Program for Community-Partnered Lung Cancer Screening
|
N/A | |
| Active, not recruiting |
NCT03164486 -
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
|
Early Phase 1 | |
| Active, not recruiting |
NCT01696968 -
Screening for Lung Cancer in Older Patients (PLCO Screening Trial)
|
N/A | |
| Recruiting |
NCT04410302 -
Patient-Derived Xenografts to Reduce Cancer Health Disparities
|
||
| Recruiting |
NCT04969341 -
Improving Lung Cancer Screening Adherence by Overcoming Barriers for Vulnerable Populations
|